The prevalence of obesity in combination with sarcopenia (the age-related loss of muscle
mass and strength or physical function) is increasing in adults aged 65 years and older. A …

Ghrelin, a peptide hormone predominantly produced by the stomach, was isolated as the
endogenous ligand for the growth hormone secretagogue receptor. Ghrelin is a potent …

BACKGROUND Cachexia, described as weight loss (mainly in lean body mass [LBM]) and
anorexia, is common in patients with advanced cancer. This study examined the efficacy and …

Background Cancer cachexia is characterized by weight loss and is associated with
increased morbidity and mortality in patients with cancer. Anamorelin (ONO‐7643; ANAM) is …

Background Cancer anorexia-cachexia syndrome is associated with increased morbidity
and mortality. Anamorelin is an oral ghrelin-receptor agonist with appetite-enhancing and …

Ghrelin is the only known peripherally-derived orexigenic hormone, increasing appetite and
subsequent food intake. The ghrelinergic system has therefore received considerable …

A breakthrough using “reverse pharmacology” identified and characterized acyl ghrelin from
the stomach as the endogenous cognate ligand for the growth hormone (GH) secretagogue …

The original definition of sarcopenia refers to the age‐related loss of muscle mass. The
literature suggests that the prevalence of sarcopenia in 60‐to 70‐year‐olds is in the range of …

Purpose Cancer cachexia is characterized by decreased body weight (mainly lean body
mass [LBM]) and negatively impacts quality of life (QOL) and prognosis. Anamorelin (ONO …

Purpose Cachexia in cancer adversely affects patients' perception of symptoms, well-being,
and response to therapy, and shortens survival. Anamorelin, an oral mimetic of ghrelin, has …